UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000024447
Receipt number R000027662
Scientific Title Verification of GLP-1 receptor agonist (Dulaglutide) additive effect on basal insulin therapy in patients with T2DM
Date of disclosure of the study information 2016/10/17
Last modified on 2019/10/20 11:14:34

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Verification of GLP-1 receptor agonist (Dulaglutide) additive effect on basal insulin therapy in patients with T2DM

Acronym

Verification of GLP-1 receptor agonist (Dulaglutide) additive effect on basal insulin therapy in patients with T2DM

Scientific Title

Verification of GLP-1 receptor agonist (Dulaglutide) additive effect on basal insulin therapy in patients with T2DM

Scientific Title:Acronym

Verification of GLP-1 receptor agonist (Dulaglutide) additive effect on basal insulin therapy in patients with T2DM

Region

Japan


Condition

Condition

Type2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Type 2 diabetes patients during treatment with basal insulin and the target , without changing the group to add administration of Dulaglutide insulin in dose loss by 50% , and the group to add administration of the Dulaglutide without changing the dose of insulin , the dose of insulin to randomly assigned to the group to add administration the Dulaglutide , the Dulaglutide administered for 24 weeks , to evaluate the efficacy and safety .

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Frequency of hypoglycemia

Key secondary outcomes

The amount of change from baseline in HbA1c.
The amount of change from baseline in bodyweight.
The amount of change from the insulin dose of baseline.
Frequency of adverse events.



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Dose comparison

Stratification


Dynamic allocation


Institution consideration

Institution is not considered as adjustment factor.

Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

The group to lose dose 50% insulin when add the Dulaglutide.

Interventions/Control_2

The group does not change the insulin dose when add the Dulaglutide.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The past three months , patients with type 2 diabetes are doing a basal insulin therapy with a fixed dose.
Patient HbA1c value of consent acquisition time of 6.5 to 10%.
Patient fasting serum CPR is greater than or equal to 0.5 ng / mL of consent acquisition point.
Patient age at the time of obtaining informed consent is 20 years of age or older.
Patients capable of obtaining the consent of the research participation by free will in writing from the person .



Key exclusion criteria

Type1 diabetes patients.
Patients receiving insulin other than basal insulin.
Patients who have used the GLP-1 receptor agonist in the past year.
Patients who have a history of pancreatitis.
During pregnancy , women who want to breast-feeding or during pregnancy .
Patients attending physician has determined that there is a clinical problem in order to participate in the study.




Target sample size

48


Research contact person

Name of lead principal investigator

1st name Yuichi
Middle name
Last name Kojima

Organization

Japan Red Cross Medical Center

Division name

Department of Diabetes and Endocrinology

Zip code

150-8935

Address

4-1-22 Hiroo Shibuya-ku Tokyo Japan

TEL

03-3400-1311

Email

kojima_yuichi@med.jrc.or.jp


Public contact

Name of contact person

1st name Takashi
Middle name
Last name Omura

Organization

Japan Red Cross Medical Center

Division name

Department of Diabetes and Endocrinology

Zip code

150-8935

Address

4-1-22 Hiroo Shibuya-ku Tokyo Japan

TEL

03-3400-1311

Homepage URL


Email

tks121@gmail.com


Sponsor or person

Institute

Japan Red Cross Medical Center

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Japan Red Cross Medical Center

Address

4-1-22 Hiroo Shibuya-ku Tokyo Japan

Tel

03-3400-1311

Email

chiken2@med.jrc.or.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

日本赤十字社医療センター(東京都)、むさし野ファミリークリニック(埼玉県)、目白内科クリニック(東京都)


Other administrative information

Date of disclosure of the study information

2016 Year 10 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

48

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2016 Year 07 Month 06 Day

Date of IRB

2019 Year 09 Month 30 Day

Anticipated trial start date

2016 Year 10 Month 01 Day

Last follow-up date

2020 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 10 Month 17 Day

Last modified on

2019 Year 10 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027662


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name